Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atazanavir/ritonavir + lamivudine maintenance versus atazanavir/ritonavir + 2 optimized NRTIs in virologically suppressed HIV-1 patients
2011-001107-12Phase 4Active
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atazanavir, ritonavir and lamivudine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: Proportion of patients with undetectable viral load at week 48. Started Sep 2011; status: active.
02
Drugs
atazanavirritonavirlamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2011-001107-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001107-12.